SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

(HealthDay News) – Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis. To identify signs of early ...

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robert F. Spiera, MD, of the Hospital for Special Surgery, spoke about the safety and efficacy of anabasum, a cannabinoid receptor ...

DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Diffuse systemic sclerosis (dSSc) can be a devastating disease, and to date there are no clearly beneficial treatments. However, the agent relaxin has shown some promise in improving skin disease. [1] ...

"Diffuse Cutaneous Systemic Sclerosis Pipeline"As per DelveInsight's assessment, globally, Diffuse Cutaneous Systemic Sclerosis pipeline constitutes 15+ key companies continuously working towards ...

MONTREAL — Mycophenolate mofetil can be substituted for cyclophosphamide for the immunosuppressive treatment of scleroderma-related interstitial lung disease, and might even be safer, according to ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...